XU Lingyun,TU Zhiqiang,XUE Haiyan,CAO Lanfang . T helper lymphocyte subsets and cytokines in children with systemic-onset juvenile idiopathic arthritis [J]., 2014, 32(2): 140-143.
[1] Srivastava S，Macaubas C，Deshpande C，et al. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis [J]. Clin Immunol，2010，136(2)：257-268. [2] 全国儿童风湿病协作组. 儿童风湿病诊断及治疗专家共识 [J]. 临床儿科杂志，2010，28(10)： 984-991. [3] 牛磊，蒋瑾瑾. Th1/Th2、Th17/Treg平衡与幼年特发性关节炎 [J]. 临床儿科杂志，2010，28(11)： 1095-1098. [4] Omoyinmi E，Hamaoui R，Pesenacker A，et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis [J]. Rheumatology (Oxford)，2012，51(10)： 1881-1886. [5] Nistala K，Moncrieffe H，Newton KR，et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis，but have a reciprocal relationship to regulatory T cell numbers [J]. Arthritis Rheum，2008，58(3)：875-887. [6] Ruperto N，Brunner HI，Quartier P，et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis [J]. N Engl J Med，2012，367(25)： 2396-2406. [7] Lin YT，Wang CT，Gershwin ME，et al. The pathogenesis of oligoarticular/polyarticularvs systemic juvenile idiopathic arthritis [J]. Autoimmun Rev，2011，10(8)： 482-489. [8] Gattorno M，Piccini A，Lasigliè D，et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis [J]. Arthritis Rheum，2008，58(5)：1505-1515. [9] Sikora KA，Fall N，Thornton S，et al. The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness [J]. Arthritis Rheum，2012 ，64(11)：3799-3808. [10] Charles AJ，Paul T，Mark W，et al. Immunobiology[M]. UK：Elsevier Health Sciences，2008：386-392. [11] McAllister F，Henry A，KreindlerJL，et al. Role of IL-17A，IL-17F，and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium： implications for airway inflammation in cystic fibrosis [J]. J Immunol，2005，175(1)：404-412. [12] Schnyder B，Schnyder-Candrian S，Pansky A，et al. IL-17 reduces TNF-induced Rantes and VCAM-1 expression [J]. Cytokine，2005，31(3)：191-202. [13] Harrington LE，Hatton RD，ManganPR，et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J]. Nat Immunol，2005，6(11)：1123-1132. [14] Fantini MC，Monteleone G，MacDonald TT. IL-21comes of age as a regulator of effector T cells inthe gut [J]. Mucosal Immunol，2008，1(2)： 110-115. [15] Jia X，Hu M，Wang C，et al. Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis [J]. Mol Vis，2011，17：1493-1507. [16] Boissier MC，Assier E，Falgaronc G，et al. Shifting the imba-lance from Th1/Th2 to Th17/treg： the changing rheumatoid arthritis paradigm [J]. Joint Bone Spine，2008，75(4)： 373-375. [17] Nistala K，Adams S，Cambrook H，et al. Th17 plasticityin human autoimmune arthritis is driven by the inflammatory environment [J]. Proc Natl Acad Sci USA，2010，107(33)：14751-14756. [18] Nistala K，Moncrieffe H，Newton KR，et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis，but have a reciprocal relationship to regulatory T cell numbers [J]. Arthritis Rheum，2008，58(3)：875-887. [19] Cosmi L，Cimaz R，Maggi L，et al. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis [J]. Arthritis Rheum，2011，63(8)：2504-2515.
